StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
AbbVie
178.91
+1.62%
 

ABBV

 

AbbVie

$ 178.91

 
+$2.86 | +1.62%
 
 
Open
$ 176.05
 
 
MKT CAP
$ 316.04B
 
High
$ 179.19
 
 
VOL
$ 3.92M
 
Low
$ 175.75
 
 
AVG VOL
$ 5.19M
 
 
 

ABBV Stock Analysis

  Login to display AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
 
 

ABBV Total Score

 
 

Strengths

ABBV Rewards

 Earnings are forecast to grow

ABBV Rewards

 Investors confidence is positive

ABBV Rewards

 Upgraded on attractively valued

ABBV Rewards

 Analysts raised price target

 
 

Chart

 
 

164.77

143.41

145.52

149.6

 
 
1month
3month
6month
1year
 

ABBV Risk Level

This Indicator assigning ABBV risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
ABBV Risk Level
LOW
HIGH

Risk Volatility

 

ABBV has Low Risk Level

Click here to check what is your level of risk

 

ABBV Analysts Opinion

ABBV overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.43
 

ABBV Earnings Sentiment

 Above analyst estimates

ABBV Earnings Sentiment

 Revenue declined YoY

 
 

Rating

×
 

Rating

3.25
 

ABBV Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.71
 

ABBV Momentum Analysis

 Price value has negative momentum

 

Activity

×
 

Activity

3.79
 

ABBV Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

3.36
 

ABBV Future Sentiment

 Earnings are forecast to grow

ABBV Future Sentiment

 Analysts raised price target

 
 

ABBV Analysts Opinion

ABBV Analysts opinion is positive and also has improved from the past 3 months

 

ABBV Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
72%
Buy
Opinion
Trend
Score
Potential
Score
 
 
25%
14%
72%
 
On Track
On Track
On Track
 

ABBV Street Opinion 

ABBV Street view is bullish and have positive views on the near-term outlook

 

ABBV Performance Sentiment

Sentiments overview associated with ABBV events and the stock performance.
 
72%
16%
Positive
Negative
73 out of 102
events present
16 out of 102
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

ABBV Earnings

The TTM reflects 12-month period, providing review of ABBV financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
55,138
58,054
56,197
-0.95%
 
 
Cost of Revenue
18,881
17,414
17,446
+4.03%
 
 
Gross Profit
36,257
40,640
38,751
-3.27%
 
 
Operating Exp
20,454
21,826
19,703
+1.89%
 
 
Operating Inc
15,803
18,814
19,048
-8.92%
 
 
Net Interest Inc
-1,782
-2,044
-2,384
-
 
 
Interest Exp
2,226
2,230
2,423
-4.15%
 
 
Interest Inc
444
186
39
+237.41%
 
 
Other Income
-6,018
-3,293
-3,675
-
 
 
EPS
3.66
6.65
6.48
-24.85%
 
 
Next Earnings Date: Apr 25, 2024
 
 
Similar to ABBV
Total Score
Close Price
%
Change

IMGN

ImmunoGen

N/A

0.00%

 

PFE

Pfizer

3.47

26.59

+0.11%

 

JNJ

Johnson & Johnson

3.48

162.12

+0.46%

 

BMY

Bristol-Myers Squibb

3.36

50.89

+0.32%

 

ABT

Abbott Laboratories

3.00

118.62

-0.02%

 
 
 
Highlights
Last Modify
Price
% Change

 
Strong Earnings
This Week
178.99
+0.10%
 
Agreements
1 Week Ago
176.75
+0.92%
 
HR Activity
1 Week Ago
175.15
-0.35%
 
HR Activity
1 Week Ago
175.75
-0.98%
 
Dividend Declares
2 Weeks Ago
176.59
+1.26%
 
 
 
joker
 
 
 
StocksRunner

Explore our ABBV Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our ABBV Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

ABBV Rewards

 Earnings are forecast to grow

ABBV Rewards

 Investors confidence is positive

ABBV Rewards

 Upgraded on attractively valued

ABBV Rewards

 Analysts raised price target

 
 
 

ABBV Risk Level

 
 
 

The Indicator assigning ABBV risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
ABBV Risk Level
LOW
HIGH

Risk Volatility

 

ABBV has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

ABBV

 

AbbVie

$ 178.91

 
+$2.86 | +1.62%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 176.05
 
 
MKT CAP
$ 316.04B
 
High
$ 179.19
 
 
VOL
$ 3.92M
 
Low
$ 175.75
 
 
AVG VOL
$ 5.19M
 
 
 

ABBV Analysis

  Sign in to view AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

164.77

143.41

145.52

149.6

 
 
1month
3month
6month
1year
 

ABBV Analysts Opinion

ABBV Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.43
 

ABBV Earnings Sentiment

 Above analyst estimates

ABBV Earnings Sentiment

 Revenue declined YoY

 
 

Rating

×
 

Rating

3.25
 

ABBV Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

2.71
 

ABBV Momentum Sentiment

 Price value has negative momentum

 

Activity

×
 

Activity

3.79
 

ABBV Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

3.36
 

ABBV Future Sentiment

 Earnings are forecast to grow

ABBV Future Sentiment

 Analysts raised price target

 
 

ABBV Analysts Opinion

ABBV Analysts opinion is positive and also has improved from the past 3 months

 

ABBV Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
72%
Buy
Opinion
Trend
Score
Potential
Score
 
 
25%
14%
72%
 
On Track
On Track
On Track
 

ABBV Street Opinion 

ABBV Street view is bullish and have positive views on the near-term outlook

 
ABBV Performance Sentiment
Sentiments overview associated with ABBV events and the stock performance.
 
72%
16%
Positive
Negative
73 out of 102
events present
16 out of 102
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

ABBV Earnings

The TTM data reflects the most recent 12-month period, providing overview of ABBV financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
55,138
58,054
56,197
-0.95%
 
 
Cost of Revenue
18,881
17,414
17,446
+4.03%
 
 
Gross Profit
36,257
40,640
38,751
-3.27%
 
 
Operating Exp
20,454
21,826
19,703
+1.89%
 
 
Operating Inc
15,803
18,814
19,048
-8.92%
 
 
Net Interest Inc
-1,782
-2,044
-2,384
-
 
 
Interest Exp
2,226
2,230
2,423
-4.15%
 
 
Interest Inc
444
186
39
+237.41%
 
 
Other Income
-6,018
-3,293
-3,675
-
 
 
EPS
3.66
6.65
6.48
-24.85%
 
 
Next Earnings Date: Apr 25, 2024
 
Highlights
Last Modify
Price
% Change

 
Strong Earnings
This Week
178.99
+0.10%
 
Agreements
1 Week Ago
176.75
+0.92%
 
HR Activity
1 Week Ago
175.15
-0.35%
 
HR Activity
1 Week Ago
175.75
-0.98%
 
Dividend Declares
2 Weeks Ago
176.59
+1.26%
 
 
ABBV Latest News Feed

Buy These 7 Dividend Aristocrats for Huge 2024 Passive Income. Since 1926 dividends have accounted for almost a third of the total return of the S&.P 500 so regardless of whether the market is up down or flat regular dividend payments from high-quality blue chip stocks provide investors with a much better chance for success. With inflation staying#dividendaristocrats #mtape #3mcompany #premium #healthcare #filtration #diy #abbvie #abbvieinc #abbottlaboratories

Fri Mar 1, 2024

Potential

AbbVie OSE Immunotherapeutics partner to develop novel monoclonal antibody.

Wed Feb 28, 2024

Activity

AbbVie partners with OSE Immunotherapeutics to develop novel nonoclonal antibody.

Wed Feb 28, 2024

Activity

AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics. (RTTNews) - AbbVie Inc. (ABBV) and OSE Immunotherapeutics SA announced a strategic partnership to develop OSE-230 a monoclonal antibody designed to resolve chronic

Wed Feb 28, 2024

Activity

Genmabs SBLA For Epcoritamab-bysp Granted Priority Review By FDA. (RTTNews) - Tuesday Genmab A/S (GMAB) and AbbVie (ABBV) revealed that the FDA has given a Priority Review to the supplemental Biologics License Application or sBLA for Epcoritamab

Tue Feb 27, 2024

Activity

ABBV Crosses Above Average Analyst Target. In recent trading shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $178.18 changing hands for $178.81/share. When a stock reaches the target an analys

Tue Feb 27, 2024

Earnings
Potential
Rating

AbbVie (ABBV) Price Target Increased by 6.12% to 182.84. The average one-year price target for AbbVie (NYSE:ABBV) has been revised to 182.84 / share. This is an increase of 6.12% from the prior estimate of 172.30 dated Januar

Sat Feb 24, 2024

Potential

AbbVie Tentarix team up for immunology oncology drug discovery.

Thu Feb 22, 2024

Activity

AbbVie Teams Up With Tentarix To Develop Multi-specific Biologics For Oncology Immunology. (RTTNews) - Drug manufacturer AbbVie Inc. (ABBV) announced a collaboration with Tentarix Biotherapeutics on Thursday to use the latters Tentacles platform

Thu Feb 22, 2024

Activity

AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active Multi-Specific Biologics for Oncology and Immunology. Collaboration to leverage AbbVies therapeutic area expertise and Tentarixs Tentacles™ platform to develop novel multifunctiona

Thu Feb 22, 2024

Activity

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael. AbbVie ABBV announced that its current president and chief operating officer Robert A. Michael has been appointed as the new chief

Wed Feb 21, 2024

Activity

AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer. to retire as AbbVie CEO to become Executive Chairman NORTH CHICAGO Ill. Feb. 20 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimou

Tue Feb 20, 2024

Activity

AbbVie taps longtime executive Robert Michael as new CEO succeeding Richard Gonzalez. Michael who is AbbVies chief operating officer will become the companys second-ever CEO since the company spun out from Abbott Laboratories in 2013. 

Tue Feb 20, 2024

Activity

AbbVie says Richard Gonzalez to step down as CEO. AbbVie said on Tuesday that Richard Gonzalez will step down from his role as chief executive officer of the drugmaker on July 1.

Tue Feb 20, 2024

Activity

AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO. (RTTNews) - AbbVie Inc. (ABBV) announced Tuesday that its board of directors has unanimously selected Robert Michael AbbVies current president and chief operating officer to

Tue Feb 20, 2024

Activity

AbbVie CEO Gonzalez Retires COO to Take Helm of Botox Maker.

Tue Feb 20, 2024

Activity

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So you might want to look at some of

Mon Feb 19, 2024

Activity

3 Magnificent Growth Stocks to Buy Right Now. In a sense every investor is a growth investor. If you focus on valuation you want to find bargain stocks that will grow more in the future than in the past. If you'.re looking for income you'.ll still l

Mon Feb 19, 2024

Potential

AbbVie declares $1.55 dividend.

Thu Feb 15, 2024

Activity

Daily Dividend Report: ABBV EQIX SSNC FNF NOV. AbbVie (ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable May 15 2024 to stockholders of record at the close of business on April 15 2024.

Thu Feb 15, 2024

Activity

AbbVie Declares Quarterly Dividend. ) today declared a quarterly cash dividend of The cash dividend is payable Since the company'.s inception in ...Full story available on Benzinga.com

Thu Feb 15, 2024

Activity

AbbVie Cuts Q1 Earnings Outlook Below View. (RTTNews) - AbbVie Inc. (ABBV) announced on Monday that it has revised down its first-quarter earnings outlook which came in below analysts estimates. Further the company reaffirmed annual income per s

Mon Feb 12, 2024

Earnings
Potential

These 17 Words From AbbVies CEO Explain Why the Stock Is Still a Buy. There are thousands of drugs on the market and there are thousands more that are no longer in use. However none has been more successful in terms of sales than AbbVies (NYSE:

Sun Feb 11, 2024

Activity
Activity
Potential

cramers lightning round: abbvie is a very good company. mad money host jim cramer rings the lightning round bell which means hes giving his answers to callers stock questions at rapid speed.

Thu Feb 8, 2024

Potential

abbvie q4: now isnt the time to buy my largest big pharma holding.

Wed Feb 7, 2024

Potential

anima biotech announces preclinical data of candidate in idiopathic pulmonary fibrosis. bernardsville n.j. feb. 07 2024 (globe newswire) -- anima biotech the tech.bio leader bringing ai to mrna biology announced today positive preclinical data of its lung

Wed Feb 7, 2024

Activity

calibr-skaggs abbvie to develop novel cell therapies for solid tumors and autoimmune diseases. (rttnews) - the calibr-skaggs institute for innovative medicines the nonprofit drug development division of scripps research said that abbvie (abbv) h

Wed Feb 7, 2024

Activity

abbvie: game changer.

Tue Feb 6, 2024

Activity

$100 invested in abbvie 10 years ago would be worth this much today. abbvie (nyse:) has outperformed the market over the past 10 years by 2.73% on an annualized basis producing an average annual return of 13.2%. currently abbvie has a market capitalizatio

Tue Feb 6, 2024

Activity

bofa raises abbvie stock pt but maintains neutral rating sees limited upside.

Mon Feb 5, 2024

Potential
Rating

 
 
 
 
 

Score Tracker

 
 
 
Based on 102 events in the last 90 days from financial news and social media. Last updated Mar 1, 2024 23:12 Wall St. time
 
 

ABBV Total Score

 
 
 
 
 
 
 
StocksRunner

Discover ABBV Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of ABBV. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our ABBV Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ABBV Stock trends

ABBV Stock performance

ABBV Stock analysis

ABBV investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker